Overview

CJC-1295/Ipamorelin is a synergistic combination of a growth hormone-releasing hormone (GHRH) analog and a growth hormone secretagogue used to stimulate natural growth hormone production.

Mechanism of Action

CJC-1295 — GHRH analog that stimulates sustained GH release from the pituitary
Ipamorelin — Selective GH secretagogue (Ghrelin mimetic) that amplifies GH pulse amplitude
Synergistic effect — Together produce more physiologic GH release than either alone
No cortisol or prolactin elevation — Ipamorelin's selectivity avoids unwanted hormonal effects

Dosing Protocols

| Protocol | Dose | Frequency | Route | |----------|------|-----------|-------| | Standard | 100mcg each | Once daily at bedtime | Subcutaneous | | Optimized | 200mcg each | Twice daily | Subcutaneous | | Loading | 300mcg each | Once daily (2 weeks) | Subcutaneous |

Safety Profile

Generally well tolerated. Common side effects include injection site reactions, mild water retention, and tingling. Should be used under medical supervision.